Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive beads take aim at brain tumours

NCT ID NCT07712770

Not yet recruiting Disease control Sponsor: Olivia Newton-John Cancer Research Institute Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This early-phase trial tests a new way to treat recurrent glioblastoma, an aggressive brain cancer. Tiny radioactive beads called SIR-Spheres® are injected into the blood vessels feeding the tumour to deliver radiation directly inside it. The study aims to see if this approach is safe and can slow tumour growth in people whose cancer has returned after standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tiny radioactive beads called SIR-Spheres® (90Y-labelled Resin Microspheres) delivered into tumour-feeding blood vessels
What this could lead to
If it works, this could offer a new treatment option for recurrent glioblastoma, a brain cancer with very few effective therapies.
What could go wrong
This is a very early pilot study with only 12 participants, so results may not apply broadly. Delivering radiation directly to the brain carries risks of damage to healthy tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA RECURRENT GLIOBLASTOMA, IDH-WILDTYPE

Contacts and locations

Locations

  • Austin Hospital

    Melbourne, Victoria, 3084, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.